Showing 11-20 of 27 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Experiences of children with early-stage T1D and their families in three Australian monitoring cohorts: what matters most for engagement in a national program? | The University of Adelaide | Jennifer Couper | Cures | 01-February-2025 to 31-January-2027 | $179,817.84 |
| Investigating the utility of urine C-peptide in early-stage T1D | The University of Adelaide | Jennifer Couper | Cures | 01-September-2024 to 31-July-2026 | $93,760.34 |
| Harnessing T cell exhaustion for type 1 diabetes prevention | St. Vincent's Institute of Medical Research | Thomas Kay | Cures | 01-November-2023 to 31-October-2026 | $2,250,000.00 |
| A simple assay to monitor autoimmune T cell responses in T1D | St. Vincent's Institute of Medical Research | Stuart Mannering | Cures | 01-November-2024 to 31-October-2025 | $122,849.00 |
| Monitoring CD4+ T-cell responses in T1D, MS and SLE | St. Vincent's Institute of Medical Research | Stuart Mannering | Cures | 01-September-2025 to 31-August-2026 | $149,998.36 |
| A synergistic approach to preventing islet allograft rejection in beta cell replacement therapy | St. Vincent's Institute of Medical Research | Seigmund Lai | Cures | 01-March-2025 to 29-February-2028 | $256,285.00 |
| Engineering an artificial pancreas in the gut for the treatment of diabetes | Monash University | Rong Xu | Improving Lives | 01-September-2025 to 31-August-2028 | $285,000.00 |
| α-MSH/MC5R axis as an adjunctive therapeutic target for type 1 diabetes | Monash University | Michael Cowley | Improving Lives | 01-August-2019 to 30-September-2025 | $716,962.40 |
| Targeted regulatory T cells to treat type 1 diabetes | Monash University | Joshua Ooi | Cures | 01-February-2023 to 31-January-2026 | $510,000.00 |
| Combination immunotherapy with abatacept and nasal insulin | Melbourne Health | John Wentworth | Cures | 01-February-2022 to 30-June-2025 | $575,000.00 |